Skip to main content

Table 4 Sensitivity analyses of the clinical risk score

From: Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study

 

Clinical Risk Score

Moderate + High Risk (≥ 4)

High Risk (≥ 6)

Value

95% CI

Value

95% CI

Sensitivity

0.19

0.09–0.36

0.17

0.03–0.49

Specificity

0.92

0.84–0.97

0.89

0.82–0.94

Positive predictive value

0.50

0.24–0.76

0.14

0.03–0.44

Negative predictive value

0.74

0.64–0.81

0.91

0.84–0.95

Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us